Four dimensional epigenome remodelling: implications for endocrine resistance in breast cancer [ 2017 - 2019 ]

Research Grant

Researchers: Prof Susan Clark (Principal investigator) ,  A/Pr Elgene Lim ,  Dr Clare Stirzaker

Brief description Patients with estrogen receptor positive breast cancer receive endocrine therapy, however half fail to respond and relapse. Endocrine resistant breast cancer currently represents the most significant challenge to breast cancer treatment. We suggest that three-dimensional epigenetic remodelling is an underlying mechanism that determines endocrine sensitivity that we will exploit as a novel therapeutic strategy to effectively treat patents with recurrent disease.

Funding Amount $AUD 847,934.74

Funding Scheme Project Grants

Notes Standard Project Grant